Thank you so much, Richard!
Anna Bensch, MLIS
Medical Librarian/CME Coordinator
CentraState Healthcare System
901 West Main Street
Freehold, NJ 07728
[log in to unmask]<mailto:[log in to unmask]>
[Description: New logo signature]
The information contained in this e-mail message is intended only for the personal and confidential use of the intended recipient(s). If you are not the intended recipient or an agent responsible for delivering the message to the intended recipient, you are hereby notified that you have received this document in error and that any review, dissemination, distribution, or copying of this message is strictly prohibited. If you have received this communication in error, please notify me at the above e-mail or phone number, and delete the original message.
From: Richard James [mailto:[log in to unmask]]
Sent: Wednesday, April 22, 2020 9:08 AM
To: Bensch, Anna <[log in to unmask]>
Cc: Medical Libraries Discussion List <[log in to unmask]>
Subject: [EXTERNAL]Re: [MEDLIB-L] Atorvastatin and COVID-19
*** EXTERNAL EMAIL - EXTERNAL EMAIL - EXTERNAL EMAIL ***
WARNING: This email originated outside of CentraState Healthcare System.
DO NOT CLICK on ANY links or attachments unless you recognize the sender and are expecting the email.
Report suspicious emails to [log in to unmask]<mailto:[log in to unmask]>
Note: Sanctions apply for inappropriate email use.
*** EXTERNAL EMAIL - EXTERNAL EMAIL - EXTERNAL EMAIL ***
Some results in Embase:
Reducing mortality from 2019-nCoV: host-directed therapies should be an option
The Lancet 2020 395 :10224 (e35 - e36)
Translated Title
Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): Study protocol for a randomized controlled trial
Trials 2018 19 :1 Article Number 81
Translated Abstract
Background: It had been more than 5 years since the first case of Middle East Respiratory Syndrome coronavirus infection (MERS-CoV) was recorded, but no specific treatment has been investigated in randomized clinical trials. Results from in vitro and animal studies suggest that a combination of lopinavir/ritonavir and interferon-β1b (IFN-β1b) may be effective against MERS-CoV. The aim of this study is to investigate the efficacy of treatment with a combination of lopinavir/ritonavir and recombinant IFN-β1b provided with standard supportive care, compared to treatment with placebo provided with standard supportive care in patients with laboratory-confirmed MERS requiring hospital admission. Methods: The protocol is prepared in accordance with the SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) guidelines. Hospitalized adult patients with laboratory-confirmed MERS will be enrolled in this recursive, two-stage, group sequential, multicenter, placebo-controlled, double-blind randomized controlled trial. The trial is initially designed to include 2 two-stage components. The first two-stage component is designed to adjust sample size and determine futility stopping, but not efficacy stopping. The second two-stage component is designed to determine efficacy stopping and possibly readjustment of sample size. The primary outcome is 90-day mortality. Discussion: This will be the first randomized controlled trial of a potential treatment for MERS. The study is sponsored by King Abdullah International Medical Research Center, Riyadh, Saudi Arabia. Enrollment for this study began in November 2016, and has enrolled thirteen patients as of Jan 24-2018.
Clinical and laboratory findings of the first imported case of middle east respiratory syndrome coronavirus to the United States
Clinical Infectious Diseases 2014 59 :11 (1511 - 1518)
Translated Abstract
Background. The Middle East respiratory syndrome coronavirus (MERS-CoV) was discovered September 2012 in the Kingdom of Saudi Arabia (KSA). The first US case of MERS-CoV was confirmed on 2 May 2014. Methods. We summarize the clinical symptoms and signs, laboratory and radiologic findings, and MERS-CoV-specific tests. Results. The patient is a 65-year-old physician who worked in a hospital in KSA where MERS-CoV patients were treated. His illness onset included malaise, myalgias, and low-grade fever. He flew to the United States on day of illness (DOI) 7. His first respiratory symptom, a dry cough, developed on DOI 10. On DOI 11, he presented to an Indiana hospital as dyspneic, hypoxic, and with a right lower lobe infiltrate on chest radiography. On DOI 12, his serum tested positive by real-time reverse transcription polymerase chain reaction (rRT-PCR) for MERS-CoV and showed high MERS-CoV antibody titers, whereas his nasopharyngeal swab was rRT-PCR negative. Expectorated sputum was rRT-PCR positive the following day, with a high viral load (5.31 × 106 copies/mL). He was treated with antibiotics, intravenous immunoglobulin, and oxygen by nasal cannula. He was discharged on DOI 22. The genome sequence was similar (>99%) to other known MERS-CoV sequences, clustering with those from KSA from June to July 2013. Conclusions. This patient had a prolonged nonspecific prodromal illness before developing respiratory symptoms. Both sera and sputum were rRT-PCR positive when nasopharyngeal specimens were negative. US clinicians must be vigilant for MERS-CoV in patients with febrile and/or respiratory illness with recent travel to the Arabian Peninsula, especially among healthcare workers.
On Wed, Apr 22, 2020 at 8:47 AM Bensch, Anna <[log in to unmask]<mailto:[log in to unmask]>> wrote:
Good morning,
I have been running searches for the use of atorvastatin for the treatment or prevention of COVID-19 infection, however I am not receiving any results. I have found a few articles on statins and COVID-19, but that's it. Any luck that anyone may find something on this topic that I'm overlooking, or could share any resources that may help find something? It could also be that this research isn't out there at this time. Thanks!
Best,
Anna Bensch, MLIS
Medical Librarian/CME Coordinator
CentraState Healthcare System
901 West Main Street
Freehold, NJ 07728
[log in to unmask]<mailto:[log in to unmask]><mailto:[log in to unmask]<mailto:[log in to unmask]>>
[Description: New logo signature]
The information contained in this e-mail message is intended only for the personal and confidential use of the intended recipient(s). If you are not the intended recipient or an agent responsible for delivering the message to the intended recipient, you are hereby notified that you have received this document in error and that any review, dissemination, distribution, or copying of this message is strictly prohibited. If you have received this communication in error, please notify me at the above e-mail or phone number, and delete the original message.
|
